Company News 30 Oct 2025 Professor Minghao Zheng elected Fellow of the Australian Academy of Health and Medical Sciences Professor Minghao Zheng, Orthocell’s Co-Founder and Chief Scientific Officer, has been elected as a Fellow of the Australian Academy of… Orthocell
Company News 29 Oct 2025 Orthocell Appoints Exclusive Remplir™ Distributor for Hong Kong Orthocell has appointed medical device distributor MontsMed as its exclusive in-country distributor for Remplir in the key Asian market of… Orthocell
Company News 20 Oct 2025 Orthocell secures global distribution rights to innovative bone regeneration technology Orthocell has signed Memorandum of Understanding to increase its equity stake in Marine Biomedical - from 1.7% to 12.0% for… Orthocell
Company News 17 Oct 2025 $30.0 Million Placement to Accelerate Global Commercialisation and Advance Product Portfolio Orthocell has today announced that it has received firm commitments for a $30 million capital raising via an institutional placement. Orthocell
Video 10 Oct 2025 Quarterly Report – period ended 30 September 2025 Orthocell has today released its Quarterly Report for the period ended 30 September 2025, outlining a period of continued growth… Orthocell
Company News 02 Oct 2025 Orthocell Announces Record Revenue of $3m for September Quarter Orthocell has announced record quarterly revenue of $3.0 million for the September quarter – our sixth consecutive quarter of record… Orthocell
Company News 30 Sep 2025 Orthocell Appoints First Distributor for Remplir™ in US$75m Canadian Market Orthocell has appointed its first Canadian distributor for Remplir™, signalling the commencement of the Company’s commercial roll out in the… Orthocell
Company News 16 Sep 2025 Global opportunity emerges as Remplir™ is used in nerve-sparing prostate cancer surgery Orthocell has identified a promising new application for its flagship Remplir™ nerve repair device - for use in nerve-sparing Robotic-Assisted… Orthocell
Company News 08 Sep 2025 Remplir™ Real World Evidence study delivers compelling 81% success rate Orthocell has today released interim results from a new Remplir™ Real World Evidence study, demonstrating an overall treatment success rate… Orthocell
Company News 13 Aug 2025 Commercialisation of Remplir™ into US Market Continues to Build Momentum Orthocell has today provided update on the continuing successful commercialisation of its flagship nerve repair product Remplir™ in the US. Orthocell
